A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England

Some patients with multiple myeloma are receiving treatment in clinical practice in England after prior exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti‐CD38 monoclonal antibody. We investigated the characteristics of these patients, their outcomes, and the salvage therapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsada, Ahmed, Zalin‐Miller, Amy, Knott, Craig, Caravotas, Leonidas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175886/
https://www.ncbi.nlm.nih.gov/pubmed/35844690
http://dx.doi.org/10.1002/jha2.214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175886/
https://www.ncbi.nlm.nih.gov/pubmed/35844690
http://dx.doi.org/10.1002/jha2.214

Ejemplares similares